[
Biochemical recurrence
PET/CT
PSMA
Prostate cancer
Zirconium-89
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
11
04
2022
accepted:
22
07
2022
pubmed:
6
8
2022
medline:
29
10
2022
entrez:
5
8
2022
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become increasingly important in the management of prostate cancer, especially in localization of biochemical recurrence (BCR). PSMA-targeted PET/CT imaging with long-lived radionuclides as Seven patients with BCR of prostate cancer who revealed no (n = 4) or undetermined (n = 3) findings on [ Intense physiological uptake was observed in the salivary and lacrimal glands, liver, spleen, kidneys, intestine and urinary tract. The parotid gland received the highest absorbed dose (0.601 ± 0.185 mGy/MBq), followed by the kidneys (0.517 ± 0.125 mGy/MBq). The estimated overall effective dose for the administration of 111 MBq was 10.1 mSv (0.0913 ± 0.0118 mSv/MBq). In 6 patients, and in particular in 3 of 4 patients with negative [ [
Identifiants
pubmed: 35930033
doi: 10.1007/s00259-022-05925-3
pii: 10.1007/s00259-022-05925-3
pmc: PMC9606102
doi:
Substances chimiques
PSMA-617
0
Gallium Radioisotopes
0
Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4736-4747Informations de copyright
© 2022. The Author(s).
Références
Urol Clin North Am. 2018 Aug;45(3):503-524
pubmed: 30031469
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):168-177
pubmed: 31529265
Int J Mol Sci. 2020 Jun 17;21(12):
pubmed: 32560337
J Nucl Med. 2020 Oct;61(10):1484-1490
pubmed: 32060214
J Nucl Med. 2021 Apr;62(4):438-445
pubmed: 33277395
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
J Nucl Med. 2022 Apr;63(4):573-583
pubmed: 34326129
Cancers (Basel). 2021 Dec 13;13(24):
pubmed: 34944875
Phys Med Biol. 2012 Jul 21;57(14):4501-26
pubmed: 22722546
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
Bioconjug Chem. 2017 Sep 20;28(9):2211-2223
pubmed: 28767228
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594
pubmed: 34725725
Clin Nucl Med. 2022 May 1;47(5):435-436
pubmed: 35234197
Ann ICRP. 2009;39(2):1-164
pubmed: 19897132
J Nucl Med. 2021 May 10;62(5):656-664
pubmed: 32917780
IEEE Trans Med Imaging. 2009 Jun;28(6):881-93
pubmed: 19150782
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
J Nucl Med. 2015 Nov;56(11):1697-705
pubmed: 26294298
EJNMMI Res. 2017 Nov 3;7(1):88
pubmed: 29098485
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2925-2934
pubmed: 33543325
Chem Sci. 2017 Mar 1;8(3):2309-2314
pubmed: 28451334
Eur Urol Oncol. 2021 Jun;4(3):339-355
pubmed: 33637464
J Nucl Med. 2017 Oct;58(10):1545-1552
pubmed: 28687599
Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076
pubmed: 34932154
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S
pubmed: 27694178
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1611-20
pubmed: 27260521
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
J Nucl Med. 2017 Aug;58(8):1196-1200
pubmed: 28663195
J Nucl Med. 2021 May 10;62(5):596-604
pubmed: 33712536